Medigen expects results from Phase 3 vaccine trial in Paraguay in Q4

Taiwan's Medigen Vaccine Biologics Corp. is accelerating a Phase 3 clinical trial in Paraguay for its COVID-19 vaccine, with the trial expected to produce key safety and efficacy data during the fourth quarter of this year, the company said Wednesday.

(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)